Combination of statin and ezetimibe: most often in only one pill and for more patients

Česká verzia

Authors: Michal Vrablík
Authors place of work: Centrum preventivní kardiologie, III. interní klinika – endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in the journal: AtheroRev 2021; 6(3): 133-137
Category: Reviews

Summary

Ezetimibe, as the only representative of a class of selective inhibitors of intestinal cholesterol absorption, has been used in clinical practice for more than 15 years. In addition to my own experience, its use in combination with statins is based on very well documented efficacy with regard to atherogenic lipid and lipoprotein levels (LDL-cholesterol decrease by another 20% after addition to a statin) and data from morbidity and mortality studies (SEAS, SHARP, IMPROVE-IT). Ezetimibe has advanced in the latest guidelines and is recommended for all those who do not reach the target values with statin monotherapy. As documented by recent epidemiological studies (DaVinci, EUROASPIRE, Lipitenclidec), the use of ezetimibe is still not common, although we have a number of suitable fixed-dose combinations which should facilitate its inclusion in treatment. The following text aims to summarize the current role of ezetimibe in the algorithm for the treatment of patients with dyslipidemia and draw attention to the practical aspects of its indication.

Keywords:

fixed combination – dyslipidemia – ezetimibe – cardivascular risk

Zdroje

Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012; 8: 415–427. Dostupné z DOI: <http://doi: 10.2147/VHRM.S33664>.
Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs Context 2018; 7: 212534. Dostupné z DOI: <http://doi: 10.7573/dic.212534>.
Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020; 41 (1): 111–188. Dostupné z DOI: <http://doi: 10.1093/eurheartj/ehz455>.
Senaratne J, Griffiths J, McDonald K et al. Evidence for cholesterol hyperabsorbers and hyperproducers based on comparative low-density lipoprotein reductions achieved by ezetimibe versus statins. J Cardiopulm Rehabil Prev 2012; 32(5):250–254. Dostupné z DOI: <http://doi: 10.1097/HCR.0b013e31825d29ee>.
Gylling H, Miettinen TA. Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. Atherosclerosis 1996; 126(2): 325–332. Dostupné z DOI: <http://doi: 10.1016/0021–9150(96)05930–8>.
Okada K, Yagyu H, Kotani K et al. Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus. Endocr J 2010; 57(10): 903–908. Dostupné z DOI: <http://doi: 10.1507/endocrj.k10e-055>.
Federici M. Effect of ezetimibe on cholesterol absorption and lipoprotein composition in diabetes and metabolic syndrome. Atheroscler Suppl 2015: 17–22. Dostupné z DOI: <http://doi: 10.1016/S1567–5688(15)50005–6>.
Rossebø AB, Pedersen TR, Boman K et al. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. N Engl J Med 2008; 359(13): 1343–1356. Dostupné z DOI: <http://doi: 10.1056/NEJMoa0804602>.
Baigent C, Landray MJ, Emberson J et al. The effects of lowering lipid LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and renal Protection): a randomized placebo-controlled trial. Lancet 2011; 377 (9784): 2181–2192. Dostupné z DOI: <http://doi: 10.1016/S0140–6736(11)60739–3>.
Tsujita K, Sugiyama S, Sumida H et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: The multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol 2015; 66(5): 495–507. Dostupné z DOI: <http://doi: 10.1016/j.jacc.2015.05.065>.
Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Eng J Med 2015; 372(25): 2378–2397. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1410489>.
Soška V. Vliv kombinace simvastatinu s ezetimibem na krevní lipidy a na kardiovaskulární příhody u diabetiků. Komentář k výsledkům subanalýzy studie IMPROVE-IT. Vnitř Lék 2015; 61(11): 965–969.
Vrablík M, Seifert B, Pakhomenko A et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis 2021. Přijato k publikaci 8/2021.
Šatný M, Mašková J, Laštůvka J et al. Profil pacientů s nekontrolovanou arteriální hypertenzí a/nebo dyslipidemií v primární péči v Česku – studie LipitenCliDec: výsledky 1. fáze. AtheroRev 2020; 5(1): 47–52.
Mayer O, Bruthans J, Rychecká M. Změny úrovně sekundární prevence ischemické choroby srdeční mezi lety 1995–2017 v České republice: porovnání studií EUROASPIRE I, II, III, IV a V. Vnitr Lek 2018; 64(12): 1190–1199.
Informace o ceně a úhradě přípravku Ezen. Dostupné z WWW: <https://www.sukl.cz/modules/medication/detail.php?code=0189178&tab=prices>.
Rozhodnutí SÚKL dostupné na www.athero.cz